• Reports

      Reports

      Stay ahead and make informed decisions with Delvens insightful analysis on key business and technological trends.

      How We Can help you
      • Healthcare
      • Automotive
      • Chemicals & Materials
      • Aerospace & Defense
      • Semiconductors & Electronics
      • Food & Beverages
      • Pharmaceutical
      • IT & Telecom
      • Energy
      • Consumer Goods & Services
  • Best Practice Guide

      Best Practice Guides

      The Delvens Best Practice Team offers practical tactics, procedures, and resources to help you address the major growth-related dos and don'ts.

      How We Can help you
      • Healthcare
      • Automotive
      • Chemicals & Materials
      • Aerospace & Defense
      • Semiconductors & Electronics
      • Food & Beverages
      • Pharmaceutical
      • IT & Telecom
      • Energy
      • Consumer Goods & Services
  • Expertise

      Expertise

      Delvens' decades of experience helps you to strategize, plan, optimize and win.

      See What we can do
      • Syndicated Research
      • Custom Research
      • Consulting
      • Implementation Support
      • Audio-Video Infographic Workshops
      • Subscription Model
      • Bundle Reports Model
      • Best Practice Guides
  • Innovation

      Innovation

      Gain thought-provoking insights on some of the biggest trends in the world to guide you in the phase of innovation.

      Let's Innovate

      Latest Chronicles

      Pharma Businesses

      Pharma businesses that are rewired will win in the digital era

      13th July 2023

      Featured Chronicle

      ESG

      Why ESG is more important than ever!

      4th November 2022
  • Innovation
  • Explore

      Explore

      From accelerating growth and providing strategic vision to the world's biggest brands, to lunch-break sneaker shopping on Melrose, and thirsty Thursdays at the local pubs. We have a Hustling atmosphere because growing together should be fun, or why do it?

      Let's Explore Something

      About

      • Who We Are
      • Why Choose Us
      • Research Methodology
      • Careers
      • Contact

      Help

      • Customer FAQs
      • How To Order
      • Delivery Method
      • Return Policy
      • Privacy Policy
      • Terms of Use
  • Newscast

      Blogs

      The Pros and Cons of Cloud Computing

      The Pros and Cons of Cloud Computing

      13th July 2023
      Let's Read

      Press Room

      Healthcare AI Innovation

      Healthcare AI innovation: a new era of patientcare

      13th July 2023
      Let's Understand

      Article

      Electric Vehicle Thermal Management System (EVTMS) Market

      19th May 2023
      Let's Study
  • Newscast
      • Blog
      • Article
      • Pressroom
Pharmaceutical Icon

Relapsed/Refractory Multiple Myeloma (RRMM) Market – Trends Forecast Till 2030

Relapsed/Refractory Multiple Myeloma (RRMM) Market, by Drug Type (Proteosome Inhibitor and Immunomodulators), Route of Administration (Oral and Parenteral), Product Type (Tablet, Capsule, Solution, Suspension), End User (Hospitals, Surgical Centres/ Clinics), and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).

  • Published Date : August 2023
  • Base Year Estimate : 2022
  • Report ID : D-PH-RRMMM-1490
  • Format :
  • Number of Pages : 590
  • Domain : Pharmaceutical
  1. Pharmaceutical
  2. Relapsed/Refractory Multiple Myeloma (RRMM) Market – Trends Forecast Till 2030
Buy Now Get Free Sample Now
REPORT SYNOPSIS
Market Snapshot Market Overview Delvens Industry Expert's Standpoint Market Portfolio Key Findings Regional Analysis Competitive Landscape Recent Developments Reasons to Acquire Report Scope
Table Of Content Frequently Asked Questions

Market Snapshot

Market Overview

The Relapsed/Refractory Multiple Myeloma (RRMM) market size was estimated at USD 2.2 billion in 2023 and is projected to reach USD 3.12 billion in 2030 at a CAGR of 4.5% during the forecast period 2023-2030.

New drugs have significantly improved the prognosis of MM, which is a type of cancer that affects plasma cells in the bone marrow. The development of multiple generations of new drugs has led to a wider range of treatment options for both newly diagnosed and relapsed/refractory MM patients. This increase in therapeutic alternatives has expanded the clinical scenario, meaning that doctors now have more options to choose from when treating MM patients. The availability of more treatment options is particularly important for RRMM patients, who have already undergone one or more rounds of treatment and may have developed resistance to certain drugs. The development of new drugs has also led to improvements in overall survival rates for MM patients, as well as longer periods of remission.

several generations of new drugs have been developed since the first decade of the 21st century, which has significantly improved the prognosis of MM. The availability of new therapeutic options has led to increased complexity in treatment approaches, as there are now more options to consider for both newly diagnosed and relapsed/refractory MM (RRMM) patients. Despite the increased complexity, the availability of new therapeutic options has extended progression-free and overall survival for RRMM patients in meaningful ways. This suggests that the development of new drugs has not only improved patient outcomes but also has economic implications for the pharmaceutical industry.

The COVID-19 pandemic has had a significant impact on businesses across all industries, including the healthcare and pharmaceutical sectors. In response to this, the U.S. Food and Drug Administration (FDA) has released guidelines to help ensure the safety of trial participants and maintain the integrity of clinical trials during the pandemic. These guidelines include general considerations that sponsors and researchers should take when conducting clinical trials during the COVID-19 health emergency. One of the key considerations is to follow good clinical practice (GCP), which is a set of ethical and scientific quality standards for designing, conducting, recording, and reporting clinical trials.

Delvens Industry Expert's Standpoint

RRMM (Relapsed Refractory Multiple Myeloma) is a type of cancer that is difficult to treat due to its complexity and the wide variety of clinical situations found in MM (Multiple Myeloma) patients before they reach the status of relapsed/refractory disease. The availability of new therapeutic options has extended progression-free and overall survival for RRMM patients in meaningful ways. These treatments are not curative, but they have improved patient outcomes and increased the number of therapeutic options available. The development of new therapies has been a key driver of the RRMM market. The emphasis on individualized treatment and the projected market growth further contribute to the expansion of the RRMM market. Individualized treatment approaches are necessary due to the complexity of RRMM. These approaches take the patient's unique clinical situation, including their age, overall health, and previous treatments. The use of individualized treatment approaches has led to the development of new therapies that target specific genetic mutations or other factors that contribute to the development of RRMM. Overall, the availability of new therapeutic options and the emphasis on individualized treatment approaches have improved patient outcomes and increased the number of treatment options available for RRMM patients.

Market Portfolio

Key Findings

  • On the basis of drug type, RRMM stands for Relapsed and Refractory Multiple Myeloma, which is a type of cancer that affects plasma cells in the bone marrow. The market trend analysis provided by the RRMM segment helps to understand the current and future market scenario of drugs used to treat this type of cancer. This segmentation is important because it allows pharmaceutical companies and investors to identify the most promising drugs and therapies in the market and make informed decisions about investment and development strategies. By analyzing the market trend of each drug and therapy, the RRMM segment can provide insights into factors such as efficacy, safety, pricing, and competition, which are critical for success in the pharmaceutical industry. The RRMM segment is particularly relevant for companies that are developing new drugs and therapies for the treatment of relapsed and refractory multiple myeloma, as it can help them to identify unmet needs in the market and develop products that address those needs.
     
  • On the basis of product type, RRMM stands for relapsed, refractory, and relapsed/refractory multiple myeloma, which are specific criteria used to define a certain type of multiple myeloma. Relapsed multiple myeloma refers to when the disease returns after a period of remission, while refractory multiple myeloma refers to when the disease does not respond to treatment or stops responding after an initial response. Relapsed/refractory multiple myeloma refers to when the disease both returns after a period of remission and does not respond to treatment or stops responding after an initial response. Identifying patients who meet the criteria for RRMM is important because they may require different treatment options than those with newly diagnosed multiple myeloma.
     
  • On the basis End-User, Patients with MM may experience relapsed/refractory disease, which means that the cancer has returned or is not responding to treatment. Before reaching this stage, MM patients may experience various clinical situations, such as partial response or stable disease, which can be used to segment the RRMM (relapsed/refractory MM) market. Segmentation refers to the process of dividing a market into smaller groups based on specific characteristics, such as disease stage or treatment history. By segmenting the RRMM market based on clinical situations, healthcare professionals can better understand the complexity of treatment approaches for this patient population. This understanding can help inform treatment decisions and improve patient outcomes by tailoring therapies to specific clinical situations.
  • The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period.

Regional Analysis

North America to Dominate the Market

  • North America is estimated to account for the largest market share during the forecast period. There are many manufacturers and suppliers in North America. As a result of the region's rapid economic growth, industrial production has expanded, feeding the desire for the treatment of multiple myeloma.
     
  • New items or technology for treatment emerge. Rising technological developments, governmental approvals and introducing new products for market growth.

 

Competitive Landscape

  • Celgene Corporation
  • Amgen Inc
  • Janssen Pharmaceuticals
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline plc
  • Sanofi
  • AbbVie Inc.
  • Bristol Myers Squibb
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Teva Pharmaceutical Industries
  • ONO Pharmaceutical
  • Merck KGaA
  • Bausch Health Companies Inc.
  • Sun Pharmaceutical Industries Ltd
  • Aurobindo Pharma
  • Hikma Pharmaceuticals PLC